469 Combining a safe PI3Kd inhibitor with chemotherapy and anti-PD1 in immunotherapy-refractory NSCLC: a proof-of-concept study to allow clinical trial design

• Published in: Journal for immunotherapy of cancer Vol. 11; no. Suppl 1; p. A527
• Main Authors: Riganti, Chiara, Scagliotti, Giorgio, Novello, Silvia, Tabbo, Fabrizio, Righi, Luisella, Neff, Laurence, Lahn, Michael, Veen, Lars Van der, Conza, Giusy Di
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd 01.11.2023; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Chemotherapy; Consent; Ethics; Immunotherapy; Lung cancer; Lymphocytes; Lymphoma; Melanoma; Regular and Young Investigator Award Abstracts

BackgroundRoginolisib (IOA-244) is a first in class allosteric modulator and non-ATP competitive PI3Kd inhibitor currently in a Phase 1 clinical study. In preclinical studies, roginolisib inhibits suppressive immune cells, such as Tregs and MDSC, while preserving proliferation and function of CD8 T...